# EDGAR Filing Document

**Accession Number:** 0001395064
**File Stem:** 0001395064-25-000128
**Filing Date:** 2025-8
**Character Count:** 4525
**Document Hash:** c15254092e0ba03dddffe7b439e19976
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001395064-25-000128.hdr.sgml**: 20250821

**ACCESSION NUMBER**: 0001395064-25-000128

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250820

**FILED AS OF DATE**: 20250821

**EFFECTIVENESS DATE**: 20250821

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TAKEDA PHARMACEUTICAL CO LTD
- **CENTRAL INDEX KEY:** 0001395064
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-24938
- **FILM NUMBER:** 251238230

**BUSINESS ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668
- **BUSINESS PHONE:** 81332782111

**MAIL ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001395064

**Date of Report:** 08/20/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** TAKEDA PHARMACEUTICAL CO LTD

**Address:** 1-1, Nihonbashi-Honcho 2-Chome, Chuo-Ku, Tokyo, M0 103-8668

**Telephone number:** 81-3-3278-2306

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 08/20/2025

**SEC File Number:** 028-24938

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 1

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER            | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                       | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Ovid Therapeutics, Inc.   | 690469101 | 07/09/2025     | To approve, on a non-binding, advisory basis, the compensation of Ovid Therapeutics, Inc.'s named executive officers   | SECTION 14A SAY-ON-PAY VOTES |        7531996 |                0 | FOR         |                                  7531996 | FOR                         |  |
| Lyell Immunopharma, Inc.  | 55083R104 | 05/15/2025     | To approve, on a non-binding, advisory basis, the compensation of Lyell Immunopharma, Inc's named executive officers   | SECTION 14A SAY-ON-PAY VOTES |         823317 |                0 | FOR         |                                   823317 | FOR                         |  |
| Standard Biotools, Inc.   | 34385P108 | 06/18/2025     | To approve, on a non-binding, advisory basis, the compensation of Standard Biotool, Inc's named executive officers     | SECTION 14A SAY-ON-PAY VOTES |          16515 |                0 | FOR         |                                    16515 | FOR                         |  |
| American Well Corporation | 03044L204 | 06/11/2025     | To approve, on a non-binding, advisory basis, the compensation of American Well Corporation's named executive officers | SECTION 14A SAY-ON-PAY VOTES |          77733 |                0 | ABSTAIN     |                                    77733 | NONE                        |  |

## N-PX: Signature Block

**Reporting Person:** Takeda Pharmaceutical Co Ltd

**By (Signature):** /s/ Amit Singh

**By (Printed Signature):** /s/ Amit Singh

**By (Title):** Senior Vice President and Head of Treasury

**Date:** 08/08/2025